MedTrace Logo

Characterization of Treatment Responses in Lymphedema

NCT03783715 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2023-10-10

No results posted yet for this study

Summary

This study is designed to investigate the treatment response of lymphedema, of the upper or lower extremity, during clinical, pharmacologic treatment of lymphedema with oral ketoprofen. Correlation of clinical responses (changes in limb volume and skin thickness) with changes in the inflammasome will help to define the molecular substrate of treatment response.

Conditions

  • Lymphedema

Interventions

DRUG

Ketoprofen

Ketoprofen 200 mg ER, taken orally, once a day for 6 months. If medication, if obtained from a compound pharmacy, dose will be 210 mg ER, taken orally once a day for 6 months.

Sponsors & Collaborators

Principal Investigators

  • Stanley G Rockson · Stanford University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-21
Primary Completion
2023-03-31
Completion
2023-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03783715 on ClinicalTrials.gov